摘要
目的探讨COX-2抑制剂塞来昔布对转移性肾癌细胞增殖和凋亡作用的影响。方法选择21例转移性肾癌患者,均经口服选择性COX-2抑制剂塞来昔布每天两次每次400 mg连续治疗,直到疾病不再进展或达到患者不能耐受药物毒性而终止。分别于处理前、用后1周、4周、12周、24周、36周,采用Western blotting法检测COX-2表达,噻唑蓝(MTT)法检测转移灶癌细胞的增殖活性。流式细胞仪检测细胞凋亡情况。结果塞来昔布处理前、用后1周、4周、12周、24周和36周,肾癌细胞中的COX-2蛋白表达水平随着作用时间的延长,表达水平越低。口服塞来昔布后与服用前相比,COX-2表达明显降低。MTT法检测表明,12周、24周、36周塞来昔布的细胞抑制率分别为(4.3±1.17)%、(33.2±5.34)%、(53.4±5.87)%,显著高于处理前的(2.16±0.57)%,表明塞来昔布可以抑制转移性肾癌细胞的增殖。流式细胞仪检测结果,塞来昔布作用12周、24周、36周后的转移性肾癌细胞凋亡率分别为(8.42±0.3)%、(15.12±1.4)%、(32.16±2.1)%,与处理前凋亡率(3.13±0.4)%比较,凋亡率显著上升(P<0.01)。结论选择性COX-2抑制剂可能通过降低COX-2表达,抑制转移肾癌细胞增殖并诱导其凋亡。
Objective To study the influence of Selective COX-2 inhibitor celecoxib in proliferation and apoptosis of metastatic renal. Methods 21 patients with Metastatic RCC were chosen and treated with Celecoxib 400 mg （p. o. ）twice a day until disease no progression or patients can not accept the toxicity. The expression COX-2 inhibitor was detected by Western blotting before treatment and the 1st,4th, 12th, 24th, 36th week after taking the medicine, while the proliferation of metastatic RCC was detected by MTT assay and apoptosis was detected by flow cytometry at the same time. Results After taking Celecoxib, the expression of COX-2 reduced as time laps. MTT assay shown that （12 weeks,24 weeks,36 weeks）the cell inhibition rates were（4.3±1.17）%, （33.2±5.34） %, （53.4±5.87）% respectively at the 1st,4th,12th,24th,36th week after taking the medicine, which was significantly higher than that of （2.16±0.57）% before treatment. Flow cytometry showed that the carcinoma a poptosis rate were （8.42±0. 3）%, （15.12±1.4）%, （32.16±2.1）% respectively at the 1st,4th, 12th, 24th, 36th week after taking the medicine. The carcinoma apoptosis rate increased significantly comparing with that of （3.13±0. 4） % before treatment（ P〈0.05）. Conclusion Selective COX-2 inhibitors may decrease the expression of COX-2, inducing proliferation and apoptosis of metastasis renal carcinoma cell.
出处
《右江医学》
2011年第1期5-7,F0004,共4页
Chinese Youjiang Medical Journal
